Thursday, 29 January 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 29 January 2026
News

Roche arrives late but with a bang

Posted 29 January 2026 AM

Roche's goal of being a top three player in the obesity market is on track following strong results in a Phase 2 trial for its prime candidate.

The pharma announced topline results of a Phase 2 trial of CT-388 in treating obesity, an investigational dual GLP-1/GIP receptor agonist it obtained when it bought Carmot Therapeutics in 2023.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (16)

Access & Reimbursement (1)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (5)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.